Phase I study of TTC-352 in patients with estrogen receptor-positive metastatic breast cancer

被引：1
|
作者：
ORegan, Ruth M. [1 ]
Hurley, Randolph [2 ]
Sachdev, Jasgit C. [3 ]
Bleeker, Jonathan [4 ]
Tonetti, Debra [5 ]
Thatcher, Gregory [5 ]
Venuti, Robert [5 ]
Dudek, Arkadiusz Z. [5 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] HealthPartners Reg Canc Care Ctr, Minneapolis, MN USA
[3] HonorHlth Res Inst TGen, Scottsdale, AZ USA
[4] Sanford Hlth, Sioux Falls, SD USA
[5] TTC Oncol, Minneapolis, MN USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT051
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT051
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase II study of pembrolizumab, letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer
    Yuan, Yuan
    Yost, Susan E.
    Lee, Jin Sun
    Egelston, Colt
    Frankel, Paul H.
    Ruel, Christopher
    Padam, Simran
    Tang, Aileen
    Martinez, Norma
    Portnow, Jana
    Yeon, Christina
    Presant, Cary
    Rajurkar, Swapnil
    Sedrak, Mina
    Patel, Niki
    Lee, Peter
    Mortimer, Joanne
    CANCER RESEARCH, 2020, 80 (04)
  • [22] A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
    Baselga, Jose
    Morales, Serafin M.
    Awada, Ahmad
    Blum, Joanne L.
    Tan, Antoinette R.
    Ewertz, Marianne
    Cortes, Javier
    Moy, Beverly
    Ruddy, Kathryn J.
    Haddad, Tufia
    Ciruelos, Eva M.
    Vuylsteke, Peter
    Ebbinghaus, Scot
    Im, Ellie
    Eaton, Lamar
    Pathiraja, Kumudu
    Gause, Christine
    Mauro, David
    Jones, Mary Beth
    Rugo, Hope S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 535 - 544
  • [23] A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
    José Baselga
    Serafin M. Morales
    Ahmad Awada
    Joanne L. Blum
    Antoinette R. Tan
    Marianne Ewertz
    Javier Cortes
    Beverly Moy
    Kathryn J. Ruddy
    Tufia Haddad
    Eva M. Ciruelos
    Peter Vuylsteke
    Scot Ebbinghaus
    Ellie Im
    Lamar Eaton
    Kumudu Pathiraja
    Christine Gause
    David Mauro
    Mary Beth Jones
    Hope S. Rugo
    Breast Cancer Research and Treatment, 2017, 163 : 535 - 544
  • [24] Prognostic Value of ModifiedIHC4Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
    Jin, Liang
    Chen, Kai
    Tan, Cui
    Li, Jianbin
    Luo, Jiayue
    Yang, Yaping
    Li, Yudong
    Li, Shunying
    Zhu, Liling
    Hu, Yue
    Liu, Fengtao
    You, Qiuting
    Peng, Min
    Jiang, Zefei
    Liu, Qiang
    ONCOLOGIST, 2020, 25 (08): : E1170 - E1180
  • [25] Efficacy of fulvestrant in treating postmenopausal patients with estrogen receptor-positive metastatic breast cancer and prognostic analysis
    Li, Tao
    Jiao, Lianghe
    JOURNAL OF BUON, 2021, 26 (01): : 189 - 195
  • [26] A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma, Cynthia X.
    Sanchez, Cesar
    Gao, Feng
    Crowder, Robert
    Naughton, Michael
    Pluard, Timothy
    Creekmore, Allison
    Guo, Zhanfang
    Hoog, Jeremy
    Lockhart, A. Craig
    Doyle, Austin
    Erlichman, Charles
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2650 - 2658
  • [27] An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
    Chandarlapaty, Sarat
    Dickler, Maura N.
    Fidalgo, Jose Alejandro Perez
    Villanueva-Vazquez, Rafael
    Giltnane, Jennifer
    Gates, Mary
    Chang, Ching-Wei
    Cheeti, Sravanthi
    Fredrickson, Jill
    Wang, Xiaojing
    Collier, Ann
    Moore, Heather M.
    Metcalfe, Ciara
    Lauchle, Jennifer
    Humke, Eric W.
    Bardia, Aditya
    CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2781 - 2790
  • [28] A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Ma, Cynthia X.
    Luo, Jingqin
    Naughton, Michael
    Ademuyiwa, Foluso
    Suresh, Rama
    Griffith, Malachi
    Griffith, Obi L.
    Skidmore, Zachary L.
    Spies, Nicholas C.
    Ramu, Avinash
    Trani, Lee
    Pluard, Timothy
    Nagaraj, Gayathri
    Thomas, Shana
    Guo, Zhanfang
    Hoog, Jeremy
    Han, Jing
    Mardis, Elaine
    Lockhart, Craig
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1583 - 1591
  • [29] A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Schram, A. M.
    Dickler, M. N.
    BREAST DISEASES, 2016, 27 (04): : 315 - 318
  • [30] Bicalutamide Plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer
    Lu, Qianyi
    Xia, Wen
    Lee, Kaping
    Zhang, Jingmin
    Yuan, Huimin
    Yuan, Zhongyu
    Shi, Yanxia
    Wang, Shusen
    Xu, Fei
    ONCOLOGIST, 2020, 25 (01): : 21 - +
12345